Journey Medical director awarded 50,000 RSUs

Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.

Journey Medical Corp director Toledano Miranda Jayne received a grant of 50,000 shares of common stock in the form of restricted stock units on July 1, 2026 under the company’s 2015 Stock Plan. These RSUs vest in three annual installments: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031.

Following this award, Toledano directly holds 168,618 shares of Journey Medical common stock, including restricted stock units that vest over various time periods. The grant reflects equity-based compensation rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Toledano Miranda Jayne

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.0001 par value	50,000	$0.00	$0.00

Holdings After Transaction: Common Stock, $0.0001 par value — 168,618 shares (Direct)

Footnotes (2)

1. F1. On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031.
2. F2. Includes restricted stock units, which vest over various time periods.

Key Figures

RSUs granted: 50,000 shares Vesting tranche 1: 16,666 shares Vesting tranche 2: 16,667 shares +3 more

6 metrics

RSUs granted 50,000 shares Restricted stock units granted on July 1, 2026

Vesting tranche 1 16,666 shares RSUs vesting on July 1, 2029

Vesting tranche 2 16,667 shares RSUs vesting on July 1, 2030

Vesting tranche 3 16,667 shares RSUs vesting on July 1, 2031

Holdings after grant 168,618 shares Total direct common stock holdings after July 1, 2026 award

Grant price per share $0.00 per share Reported transaction price for RSU award

Key Terms

restricted stock units, 2015 Stock Plan, par value, vest

4 terms

restricted stock units financial

"the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2015 Stock Plan financial

"pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule"

par value financial

"Common Stock, $0.0001 par value"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

vest financial

"which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What did Journey Medical Corp (DERM) director Toledano Miranda Jayne receive in this Form 4?

Director Toledano Miranda Jayne received a grant of 50,000 restricted stock units of Journey Medical Corp common stock on July 1, 2026 as equity-based compensation under the company’s 2015 Stock Plan, rather than through an open-market purchase.

What is the vesting schedule for the 50,000 RSUs reported by Journey Medical (DERM)?

The 50,000 restricted stock units vest over three years: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031, subject to the terms of Journey Medical’s 2015 Stock Plan.

How many Journey Medical (DERM) shares does Toledano Miranda Jayne hold after this RSU grant?

After the July 1, 2026 grant, Toledano Miranda Jayne directly holds 168,618 shares of Journey Medical common stock, which includes restricted stock units scheduled to vest over various future periods as described in the Form 4 footnotes.

Was the Journey Medical (DERM) Form 4 transaction an open-market stock purchase or sale?

The Form 4 reports a grant of restricted stock units coded as a grant or award, not an open-market purchase or sale. The RSUs were awarded at a stated price of $0.00 per share as part of equity compensation.

Under which plan were the 50,000 Journey Medical (DERM) RSUs granted?

The 50,000 restricted stock units were granted pursuant to Journey Medical Corp’s 2015 Stock Plan, as amended, which governs the terms, vesting schedule, and other conditions for this equity compensation award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Toledano Miranda Jayne

(Last) (First) (Middle)

C/O JOURNEY MEDICAL CORPORATION

9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)

SCOTTSDALE ARIZONA 85258

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value	07/01/2026		A		50,000(1)	A	$0	168,618(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031.

2. Includes restricted stock units, which vest over various time periods.

	/s/ Ramsey Alloush, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)